Bristol-Myers Squibb Co. and ImClone Systems Inc. said a late-stage trial of their cancer drug Erbitux used along with another treatment in metastatic colorectal cancer failed to ensure overall survival.
The study compared irinotecan with irinotecan plus Erbitux in about 1,300 patients whose colorectal cancer was not responding to first-line oxaliplatin-based chemotherapy, the companies said.
The primary endpoint of overall survival was not met, said the companies' joint news release on Monday.